Mississippi Clinical Trials Report — May 2026

For Mississippi residents considering participation in clinical research, May 2026 brings a critical reminder to act swiftly, especially for those interested in studies nearing their enrollment deadlines. Across the state, 23 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 2 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various conditions, from inflammatory diseases to specific types of cancer and neurological disorders, are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Acute gouty arthritis
• Acute infection
• Advance care planning
• Advance directives
• Age-related macular degeneration
• Anatomic stage II breast cancer AJCC v8
• Anatomic stage III breast cancer AJCC v8
• Atopic dermatitis
• Attention-deficit/hyperactivity disorder
• Avascular necrosis

If you or someone you know is affected by these conditions, now is the time to investigate these opportunities. Details on specific trials can be found by searching for the conditions mentioned.

Groundbreaking Research Arrives in Mississippi

This month, Mississippi welcomes 2 significant new clinical trials, both sponsored by Novo Nordisk A/S. These Phase 3 drug trials represent major advancements in the treatment of widespread health challenges, offering participants the chance to engage with cutting-edge therapies from a leading pharmaceutical company. Both studies are industry-sponsored, reflecting a strong commitment to developing new treatments.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight. This research could significantly impact the management of these interconnected conditions.
• Another pivotal Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes. Given the widespread prevalence of obesity and type 2 diabetes, this study offers a promising avenue for new treatment options.

Both of these new trials are actively seeking participants, and both include older adults as eligible participants, ensuring that a broad age range can contribute to these important studies.

Mississippi's Expanding Research Footprint

Mississippi continues to be a hub for medical research, with a total of 368 clinical trials currently recruiting across 38 cities and 233 research sites. This broad distribution ensures that opportunities are available to residents throughout the state, not just in major metropolitan areas.

This month saw the opening of 2 new clinical trials, a decrease compared to the 4 trials that launched in April 2026 and the 7 in March 2026. While the number of new openings is lower this month, the quality and potential impact of the new studies, particularly the large Phase 3 trials from Novo Nordisk, remain high.

The new studies this month have opened in diverse locations, highlighting the statewide reach of clinical research:

• Belzoni
• Diamondhead
• Jackson

These new trials are focused on conditions that affect a significant portion of the population:

• Obesity
• Heart failure
• Type 2 diabetes

Both new trials are drug-based interventions, reflecting an ongoing effort to develop pharmaceutical solutions for complex health issues.

Opportunities for All Participants

While none of the 2 new trials opened this month are specifically recruiting healthy volunteers, there are still ample opportunities for individuals without specific health conditions to contribute to medical science in Mississippi. Currently, 25 clinical trials statewide are actively recruiting healthy volunteers. These studies play a crucial role in establishing baseline data and understanding how treatments affect individuals without pre-existing conditions.

For those interested in the new trials, both studies are open to older adults, providing valuable opportunities for this demographic to participate in research that could lead to improved health outcomes for their age group. There are no new trials this month that are exclusively for children, females, or males.

The consistent presence of major industry sponsors like Novo Nordisk A/S underscores the credibility and potential impact of the research being conducted in Mississippi. These collaborations bring significant resources and expertise to the state's clinical trial landscape.

As we look ahead, Mississippi's commitment to advancing medical knowledge through clinical research remains strong. The ongoing enrollment in these vital studies, coupled with the continuous development of new research initiatives, promises to bring further opportunities for residents to contribute to and benefit from medical breakthroughs.